title: Atomoxetine-induced myocardial infarction.
abstract: Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, AtlantiCare Regional Medical Center, Atlantic City, NJ, USA. doctorseifi@gmail.com
authors.forename: Ali
authors.initials: A
authors.lastname: Seifi
authors.forename: Heidi
authors.initials: H
authors.lastname: Griffith
authors.forename: Sahar
authors.initials: S
authors.lastname: Avestimehr
authors.forename: Haitham
authors.initials: H
authors.lastname: Dib
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced*; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride